Neuphoria Therapeutics Inc.
NEUP
$4.67
$0.081.74%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 15.46% | -9.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -58.50% | -2.92% | |||
| Operating Income | 58.50% | 3.14% | |||
| Income Before Tax | 118.40% | -8.64% | |||
| Income Tax Expenses | 0.00% | 86.95% | |||
| Earnings from Continuing Operations | 118.82% | -11.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 118.82% | -11.51% | |||
| EBIT | 58.50% | 3.14% | |||
| EBITDA | 60.27% | 3.24% | |||
| EPS Basic | 109.32% | 5.60% | |||
| Normalized Basic EPS | 115.27% | 10.37% | |||
| EPS Diluted | 82.43% | 5.60% | |||
| Normalized Diluted EPS | 115.27% | 10.37% | |||
| Average Basic Shares Outstanding | 101.96% | 18.13% | |||
| Average Diluted Shares Outstanding | 101.96% | 18.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||